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ExtractAbstract The aqueous extract of Mangifera indica is known to possess diverse medicinal
properties, which also includes anti-snake venom activities. However, its inhibitory potency and
mechanism of action on multi-toxic snake venom phospholipases A2s are still unknown. Therefore,
the objective of this study was to evaluate the modulatory effect of standard aqueous bark extract of
M. indica on NN-XIb-PLA2 of Indian cobra venom. The in vitro sPLA2, in situ hemolytic and
in vivo edema inhibition effect were carried out as described. Also the effect of substrate and calcium
concentration was carried out. M. indica extract dose dependently inhibited the GIA sPLA2
(NN-XIb-PLA2) activity with an IC50 value of 7.6 lg/ml. M. indica extract effectively inhibited
the indirect hemolytic activity up to 98% at 40 lg/ml concentration. Further, M. indica extract
(0–50 lg/ml) inhibited the edema formed in a dose dependent manner. When examined as a
function of increased substrate and calcium concentration, there was no relieve of inhibitory effect
of M. indica extract on the NN-XIb-PLA2. Further, the inhibition was irreversible as evident from
binding studies. The in vitro inhibition is well correlated with in situ and in vivo edema inhibiting
activities of M. indica. As the inhibition is independent of substrate and calcium and was
irreversible, it can be concluded that M. indica extract mode of inhibition could be due to direct
interaction of components present in the extract with the PLA2 enzyme. The aqueous extract ofus, Jain
372 B.L. Dhananjaya et al.M. indica effectively inhibits svPLA2 enzymatic and its associated toxic activities, which substanti-
ate their anti-snake venom properties. Further in-depth studies on the role and mechanism of the
principal constituents present in the extract, responsible for the anti-PLA2 activity will be interest-
ing to develop them into potent antisnake component and also as an anti-inflammatory agent.
 2016 The Authors. Production and Hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Snakebite envenomation is a significant public health problem
causing considerable high morbidity and chronic mortality
around the world, particularly in the tropical and subtropical
regions (Kasturiratne et al., 2008; Warrell, 2010). It is also of
biomedical importance with social and economic impact on
developing regions around the world. Snakebite is now recog-
nized as a highly Neglected Tropical Disease (NTD) by the
World Health Organization (WHO) (Kasturiratne et al.,
2008; Warrell, 2010) and it estimates that, globally, at least
4,21,000 envenoming and 20,000 deaths occur each year due
to snakebite (Kasturiratne et al., 2008). The high mortality
and morbidity of snakebite are due to its venom, which con-
sists of a complex mixture of biologically active components,
that interfere with the course of several biological processes
in both prey and human (Aird, 2002; Dhananjaya et al.,
2010). Therefore, the pathophysiological effects observed in
snakebites are due to the combined action of several enzymes,
proteins and peptides, which include phospholipase A2, hem-
orrhagic metalloproteases and other proteolytic enzymes,
coagulant components, neurotoxins, cytotoxins and cardiotox-
ins, among others (Aird, 2002; Koh et al., 2006; Dhananjaya
et al., 2010).
The snake venom phospholipase A2 (svPLA2s) are the main
multi-toxic and lethal component of snake venom and have
been investigated because they not only have a wide range of
biological effects, but also due to their similarity to mam-
malian phospholipases (Kini and Chan, 1999). In snake ven-
oms, only two groups of secretory PLA2s (GI and GII) have
been identified. Group I (GIA) includes the svPLA2s from
Elapinae and Hydrophiinae venoms with 115–120 amino acid
residues and these svPLA2s are homologous to mammalian
pancreatic GIB sPLA2. Group II (GIIA and GIIB) comprises
the svPLA2s from Crotalinae and Viperinae venoms with 120–
125 amino acid residues and homologous to mammalian non-
pancreatic Group II-A sPLA2 (Burke and Dennis, 2009).
Group II PLA2s are in turn divided into different subgroups
on the basis of amino acid residue in the 49th position: catalyt-
ically active D49 enzymes, catalytically inactive or with low
activity K49, S49, N49 or R49 forms (Nevalainen et al.,
2012; Lomonte et al., 2009).
The above described subgroups exhibit a wide variety of
physiological and pathological effects. In addition to their pos-
sible role in the digestion of prey, snake venom sPLA2s exhibit
a wide spectrum of pharmacological effects such as neurotox-
icity, cardiotoxicity, myotoxicity, anticoagulant and anticancer
effects (Doley et al., 2010; Kini, 2003). Due to the prominent
role played by PLA2s in the snake envenomation, there is enor-
mous pharmacological interest in search of sPLA2 inhibitors
(Narendra Sharath Chandra et al., 2007; Nanda et al., 2007;
Sivaramakrishnan et al., 2016). Further, considering thelimitations of antiserum therapy (Dhananjaya et al., 2011;
Girish and Kemparaju, 2011), researches are focusing on the
development of alternative treatments and in this regard find-
ing inhibitors of the multi-toxic svPLA2s from medicinal
plants have gained much interest (Carvalho et al., 2013;
Gomes et al., 2012). In this context, although many sPLA2
inhibitors have been isolated from various medicinal plants
(Springer, 2001; Nanda et al., 2007; Narendra Sharath
Chandra et al., 2007) that have been demonstrated to bring
down the toxic and lethal effects of several venoms (Girish
and Kemparaju, 2011), however, still effective and specific
inhibitors of sPLA2 are not available.
Mangifera indica L. (Anacardiaceae) is one of the most
popular edible fruit yielding trees that grow in the tropical
and subtropical regions of the world.M. indica has been tradi-
tionally used to treat various diseases (Chopra et al., 1956; Coe
and Anderson, 1996; Shah et al., 2010; Dhananjaya et al.,
2011). The standard aqueous stem bark extract of M. indica
has been used in pharmaceutical formulations in Cuba under
the brand name VIMANG, to treat patients suffering from
increased stress (Guevara et al., 1998). The pharmacological
studies have indicated that VIMANG has immunomodula-
tory, analgesic, antinociceptive, antioxidant and anti-
inflammatory effects (Makare et al., 2001; Garrido et al.,
2004; Ojewole, 2005; Dhananjaya and Shivalingaiah, 2016).
Recently, it has been demonstrated for its potential antibacte-
rial, anti-hyperalgesic, anti-arthritic, antimutagenic, antihepa-
totoxic, anticancer and larvicidal activities (Garrido-Sua´rez
et al., 2014; Morffi et al., 2012; Rajakumar et al., 2015;
Singh et al., 2015; Awad El-Gied et al., 2015; Fahmy et al.,
2016; Khurana et al., 2016). In an earlier study, it was shown
that the aqueous steam bark extract of M. indica L. (Anacar-
diaceae) inhibited the toxic and lethal effects of Indian Rus-
sell’s viper venom (Dhananjaya et al., 2011); however, the
extract’s effect on multi-toxic and lethal PLA2s was not exem-
plified. Therefore, the objective of this study was to carry out
investigations in regard to evaluating the modulatory effect of
standard aqueous extract of M. indica on Group IA svPLA2
(i.e. purified NN-XIb-PLA2 phospholipase A2 enzyme from
Naja naja venom). Also, studies were carried out to get an
insight into the possible biochemical interaction of extract/-
components to bring about inhibition/neutralization of
svPLA2s toxic effects. This study may provide better under-
standing on the therapeutic molecular interactions of compo-
nents with antiophidian activity to supplement the
conventional antivenom therapy against these toxic and lethal
multifunctional enzymes.
2. Materials and methods
Venom from Naja naja was purchased from Irula Co-operative
Society Ltd., Chennai, India. All other reagents and chemicals
Anti-phospholipase A2 activity of Mangifera indica L. 373used were of analytical grades purchased from Sisco Research
Laboratories (SRL), Bangalore, India.
2.1. Preparation of standard aqueous stem bark extract of M.
indica L.
M. indica stem bark was collected in the university campus and
was authenticated at the university herbarium centre, Depart-
ment of Botany, University of Mysore, Mysore, India, where a
voucher specimen (UOM/DOSB/PL/82) was deposited. The
stem bark extract of M. indica was prepared by decoction
for 1 h according to the method of Garrido et al. (2004) as
described earlier (Dhananjaya et al., 2011). The fine brown
powder obtained after desiccation was dissolved in saline
and used for neutralization assays. The amount of extract is
expressed as dry weight.
2.2. Animals
Swiss Wister albino mice weighing about 20–25 g were
obtained from the central animal house facility. All protocols
of animal experiments have been approved by the Sri Adichun-
chanagiri College of Pharmacy – Institutional Animal Care
and Use Committee (IACUC). Animal care and handling were
conducted in compliance with the national regulations for ani-
mal research.
2.3. Isolation of secretary phospholipase A2 (NN-XIb-PLA2)
from the venom Naja naja
sPLA2 belonging to group IA – NN-XIb-PLA2 from the
venom Naja naja (Southern region) was purified up to homo-
geneity as described previously by the method of
Rudrammaji and Gowda (1998). This protein was further used
for evaluating the anti-inflammatory potential of aqueous
extract of M. indica. The protein concentration was estimated
according to the method of Lowry et al. (1951) using BSA as
protein standard.
2.4. Inhibition of Phospholipase A2 activity by standard aqueous
stem bark extract of M. indica L.
The Phospholipase A2 assay was carried out according to the
method as described by Bhat and Gowda (1989). Phosphatidyl
choline (PC) was diluted with petroleum ether (60–80 C) to
get a concentration of 1000 nmoles/50 ml. The reaction mix-
ture containing NN-XIb-PLA2 (3 lg) was made up to 680 ml
with water. To the reaction mixture, 200 ll of ether, 100 ll
of Tris–HCl buffer (0.05 M, pH 7.5), and 20 ll of CaCl2
(500 mM) were added. The total reaction mixture was incu-
bated at 370C for 60 min. After incubation, 0.5 ml of Doles
mixture (Isopropanol:Pet ether:NH2SO4, 40:10:1) was added,
mixed and centrifuged at 1000 rpm for 3 min. To the organic
phase 0.5 ml of CHCl3:Pet ether (1:5) was added, mixed and
centrifuged at 1000 rpm for 3 min. To the upper phase cobalt
reagent [1.35 ml of Triethanolamine made up to 10 ml with
solution A (6 g of CO(NO3)26H2O + 0.8 ml glacial acetic
acid) and 7 ml of solution B (Saturated Na2SO4)] was added,
mixed and centrifuged 1000 rpm for 3 min. The upper organic
phase was carefully transferred and 0.75 ml of a-nitroso-b-naphthol reagent (0.4% a-nitroso-b-naphthol in 96% ethanol)
was added. The intensity of the orange color is directly propor-
tional to the amount of cobalt present. After 30 min, 2 ml of
ethanol was added to dilute the contents and absorbance was
read at 540 nm. The amount of free fatty acid released was esti-
mated using standard linolenic acid curve. The enzyme activity
was expressed as nmoles of fatty acid released/min/mg of
protein.
For inhibition studies, NN-XIb-PLA2 (3 lg) was preincu-
bated with or without different concentrations of aqueous
extract of M. indica (0–15 lg/ml) at 37 C for 15 min. Appro-
priate controls were carried and further experiments were car-
ried out as described above. The inhibition is expressed as
percentage taking activity of venom alone as 100%. IC50 val-
ues were calculated using Graphpad version 5.0.
2.5. Effect of substrate and calcium concentration on NN-XIb-
PLA2 inhibition by standard aqueous stem bark extract of
M. indica L.
Effects of substrate and calcium concentrations on inhibition
of NN-XIb-PLA2 (3 lg) at IC50 concentration of extract were
determined as follows. In general, the reaction mixture con-
taining NN-XIb-PLA2 alone and/or with the IC50 concentra-
tion of aqueous extract of M. indica, in 0.05 M Tris –HCl
buffer, pH 7.5, and 400 mM calcium was used for the PLA2
assay. In the substrate-dependent assay, substrate concentra-
tion in the range of 20–120 nM was used as in the final reaction
mixture. The calcium-dependent assay was carried out of con-
centrations ranging from 0 to 15 mM in the final reaction mix-
ture. After the reaction time, PLA2 assay was carried out as
described above.
2.6. Determination of binding characteristics and reversibility of
inhibition by standard aqueous stem bark extract of M. indica L.
The reaction mixture containing NN-XIb-PLA2 (3 lg) with
the IC50 concentration of aqueous extract of M. indica in
0.05 M Tris–HCl buffer, pH 7.5, and 40 mM calcium was
pre-incubated for 15 min. Then the reaction mixture was dia-
lyzed against 1000 ml of 100 mM Tris–HCl buffer, pH 7.5,
containing 0.2 mM Ca at 4 C in dialysis tubing (with a molec-
ular weight cutoff of 3000–6000) for 24 h with three buffer
changes. The PLA2 activity was assayed before and after dial-
ysis as described above.
2.7. Neutralization of indirect hemolytic activity by standard
aqueous stem bark extract of M. indica L
Indirect hemolytic activity was assayed as described by Boman
and Kaletta (1957), using packed human erythrocytes (blood
group A). The human erythrocytes used for the study were
sourced from previously published work, which had ethical
approval from ethical committee of the University of Mysore
(UOM) for the withdrawal of blood (Dhananjaya et al.,
2011). Further, the ethics committee approval was obtained
for the use of human material in our current work. The written
informed consent from the donor was obtained for the use of
this sample in this research. The substrate for the indirect
hemolytic assay was prepared by suspending 1 ml of packed
Table 1 IC50 value and specific activity of NN-XIb-PLA2.
sPLA2 Specific activity
a IC50
b
NN-XIb-PLA2 172.4 ± 3.1 7.6 lg/ml
a nmoles of fatty acid released/mg of protein/min at 37 C.
b IC50 value is defined as the amount of extract (lg/ml) required
to inhibit 50% of enzyme activity in the given reaction mixture.
374 B.L. Dhananjaya et al.fresh human red blood cells and 1 ml fresh hen’s egg yolk in
8 ml of phosphate buffered saline (PBS). Aqueous extract of
M. indica (0–40 lg/ml) was pre-incubated with or without
NN-XIb-PLA2 (8 lg), which showed 100% hemolytic activity,
for 30 min at 37 C. To the pre-incubated sample, 1 ml of sub-
strate was added and allowed to react for 45 min at 37 C. The
reaction was stopped by adding 9 ml of ice-cold PBS. The sus-
pension was mixed and centrifuged at 1500g for 20 min. The
released hemoglobin was read at 530 nm. A sample with
venom alone served as positive control. The hydrolysis of ery-
throcyte caused by the addition of 9 ml distilled water was
taken as 100%. Appropriate controls were carried out and
the inhibition is expressed as percentage (%). Values are pre-
sented as the mean of four independent determinations.
2.8. Neutralization of edema inducing activity by standard
aqueous stem bark extract of M. indica L
The procedure of Yamakawa and Hokama (1976) as modified
by Vishwanath et al. (1987) was followed. NN-XIb-PLA2
(5 lg) was pre-incubated without or with different concentra-
tion of aqueous extract ofM. indica (0–50 lg/ml) in a total vol-
ume of 20 ll saline. The reaction mixture was injected into
intra plantar surface of right hind footpad of mice weighing
20–25 g. The left footpad that received 20 ll of saline served
as control. After 45 min, the mice were sacrificed by giving
anesthesia (Pentobarbitone, 30 mg/kg, i.p.) and both hind
limbs were removed at the ankle joint and weighed individu-
ally. The increase in weight due to edema is expressed as the
ratio of the weight of edematous limb to the weight of normal
(sham injected) limb  100. Minimum edema dose is defined as
the microgram of protein causing an edema ratio of 120%.
Injecting a fixed dose protein into mice footpads and sacri-
ficing them at regular period of time obtained time course
curve of edema inducing activity. Edema ratio was calculated
and expressed as %.
2.9. Statistical analysis
The IC50 values were calculated using Graph Pad version 5.0.
Inhibition percentages were calculated from the difference
between inhibitor-treated group and control animals, which
received the vehicle. Student’s t-test for comparisons of
unpaired was used for statistical evaluation.
3. Results and discussion
Snake venom PLA2s belonging to elapidae family are known
to be multi-toxic and lethal (Doley et al., 2010; Kini, 2003).
Due to the prominent role of PLA2s play in snake envenoma-
tion, there is enormous pharmacological interest in search of
PLA2 inhibitors (Narendra Sharath Chandra et al., 2007;
Nanda et al., 2007). Further, considering the limitations of
antiserum therapy (Dhananjaya et al., 2011; Girish and
Kemparaju, 2011), it is justified that research has to focus on
developing alternatives and in this regard finding inhibitors
of the multi-toxic svPLA2s from medicinal plants have gained
much interest in the recent past (Carvalho et al., 2013; Gomes
et al., 2012). Although many sPLA2 inhibitors have been iso-
lated from various medicinal plants (Springer, 2001; Nanda
et al., 2007; Narendra Sharath Chandra et al., 2007), however,still effective and specific inhibitors of sPLA2 are not available.
In these line of studies, the aqueous steam bark extract of
M. indica is evaluated for its potential to inhibit phospholipase
A2 (PLA2) belonging to group IA i.e. NN-XIb-PLA2, which
was isolated from R. viper venom as per the previously
described method (Rudrammaji and Gowda, 1998).
The sPLA2 belonging to group IA i.e. NN-XIb-PLA2 gave
a specific activity of around 172.4 ± 3.1, when measured using
PC as substrate (Table 1). When pre-incubated with different
concentration of extract it was observed that the aqueous
extract of M. indica, inhibited the enzymatic activity in a con-
centration dependent manner as shown in Fig. 1. The results
show that the extent of inhibition was >95% at the 40 lg/
ml of extract used. The IC50 values calculated by linear XY
scattered plot were 7.6 lg/ml (Table 1). Most of the sPLA2
inhibitors are known to inhibit the activity either by binding
to substrate or by chelating calcium, which is required for
activity. Also, it is observed that the sPLA2 inhibitors affect
the ‘‘Quality of interface” by modifying the phospholipid
bilayer properties which render the phospholipids inaccessible
to the enzyme. The steroid inducible inhibitors of PLA2 like
lipocortin I and II are shown to inhibit PLA2s by nonspecific
binding to the membrane phospholipids. It is observed that
their inhibition is relieved by increasing the substrate concen-
tration (Davidson et al., 1987). In this study, it was observed
that, when examined as a function of substrate concentration,
there was no relieve of inhibition of the extract pre-incubated,
as the substrate concentration was increased from 20 to
120 nM (Fig. 2). This suggests that the inhibition is indepen-
dent of substrate concentration. Further, in the calcium depen-
dent activity test, it was observed that an increase in calcium
concentration from 2.5 to 15 mM, increased NN-XIb-PLA2
enzymatic activity in a dose dependent manner. However,
while when IC50 concentration of M. indica extract was used
along with varying concentration of calcium, there was no
relieve of inhibition (Fig. 3), suggesting that the inhibition by
M. indica extract is independent on calcium concentration.
These all studies show that inhibition by aqueous extract of
M. indica is independent on substrate and calcium concentra-
tion. Further, it is reported that some of the PLA2 inhibitors
are shown to mediate displacement of catalytically essential
calcium from the enzyme and thus inhibition of enzymatic
activity (Pruzanski et al., 1992). In the calcium binding studies
experiments, it was found that the PLA2 enzyme activity both
before and after the dialysis of the enzyme inhibitor mixture
was unaltered i.e., the % of inhibitory activity of M. indica
extract was not decreased upon extensive dialysis, suggesting
that the inhibition is irreversible, supporting the observation
that inhibition byM. indica extract is independent on substrate
and calcium concentration. These studies indicate that the
inhibition could be due to direct interaction of components/
molecules present in M. indica extract at active site residues
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Figure 1 Dose dependent inhibition of in vitro PLA2 (NN-XIb-
PLA2) activity by aqueous stem bark extract of M. indica. Briefly,
Phosphatidyl choline (PC) corresponding to 1000 nmoles/ml was
made up to 680 ll with NN-XIb-PLA2 (5 lg), with or without
aqueous stem bark extract of M. indica at various concentrations
(0–20 lg/ml) and was incubated with other reaction mixture at
37 C for 60 min and color developed was read at 540 nm. The
results show ±S.E.M. for n= 3.
Anti-phospholipase A2 activity of Mangifera indica L. 375of the sPLA2 enzyme. NN-XIb-PLA2 enzyme exhibited indi-
rect hemolytic activity, which is an indirect way of measuring
PLA2 activity using egg yolk and washed erythrocytes are used
as substrates. When the effect of aqueous extract of M. indica
at different concentrations (0–40 lg/ml) was tested it was
found that the extract in general effectively inhibited indirect
hemolytic activity up to 98% at 40 lg/ml concentration
(Fig. 4). This in situ inhibition activity is well correlated with
the inhibitory activity of the in vitro PLA2 enzyme. Therefore,
the inhibition of NN-XIb-PLA2 activity by molecules in M.Figure 2 Dose dependent Inhibition of indirect hemolytic activity
NN-XIb-PLA2 (5 lg) in 100 ll of phosphate-buffered Saline (PBS) wa
indica at various concentrations (0–40 lg/ml). The reaction was started
10 min at 37 C. The released hemoglobin in the supernatant was mea
for n= 3.indica extract could be attributed to the modulation of the cat-
alytic activity of PLA2 at the interface itself, i.e., beyond the
initial steps of enzyme adsorption and activation, probably
through modifications of the intermolecular organization of
the membrane components. It is well known that secretory
PLA2s cause cell membrane asymmetry by degradation of
glycerol phospholipids of the membranes.
Many of the snake venom PLA2s induce toxic effect such as
edema when injected into mouse footpad as demonstrated
before (Vishwanath et al., 1988). Several svPLA2 inhibitors
are demonstrated to exhibit concomitant inhibition of enzyme
activity and edema-inducing activity (Nanda et al., 2007;
Mohamed et al., 2010). Since in our study, as the aqueous
extract of M. indica effectively inhibited the in vitro PLA2
activity and in situ PLA2 activity, the inhibitory potential on
in vivo edema inducing activity of NN-XIb-PLA2 was tested.
The edema inducing effect of NN-XIb-PLA2 (6 lg) was more
than 176%, when compared to the saline injected mice.
Fig. 5 shows that aqueous extract ofM. indica at different con-
centrations (0–40 lg/ml), dose dependently inhibited the
edema formation, when co-injected with enzyme. In addition,
M. indica extract at the tested dose alone did not cause edema
when injected into mice footpads. The neutralization of edema
inducing activity is known to be well correlated with the
in vitro enzymatic activity inhibition. It has been demonstrated
that the standard extract of M. indica, administered orally
(50–200 mg/kg body wt.) had reduced edema induced by
arachidonic acid (AA) and phorbol myristate acetate (PMA)
in mice (Garrido et al., 2006). In addition, the extract was
demonstrated to inhibit the edema induced by carrageen and
formalin in mice, rats and guinea-pigs (Garrido et al., 2004;
Ojewole, 2005). Further, it has been shown to reduce the
tumor necrosis factor alpha (TNF alpha) serum levels in both
arachidonic acid (AA) and phorbol myristate acetate (PMA)of NN-XIb-PLA2 by aqueous stem bark extract of M. indica.
s preincubated with or without aqueous stem bark extract of M.
by adding erythrocytes, egg yolk and PBS (1:1:8 v/v) incubated for
sured by taking absorbance at 540 nm. The results show ±S.E.M.
Figure 3 Dose dependent neutralization of edema inducing activity of NN-XIb-PLA2 by aqueous stem bark extract of M. indica. The
reaction mixture 30 ll containing NN-XIb-PLA2 (6 lg) was incubated for 30 min with increasing concentration of aqueous stem bark
extract (0–50 lg/ml) of M. indica. Saline (30 ll) injected into the mouse foot-pad served as control. Data represent ±S.E.M. for n= 3.
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Figure 4 Effect of substrate concentration on inhibition of
NN-XIb-PLA2 by aqueous stem bark extract of M. indica. The
reaction mixture contained NN-XIb-PLA2 enzyme in 0.05 M
Tri–HCl buffer pH 7.5, 500 mM CaCl2, inhibitors, and increasing
concentrations of substrate. The reaction was carried out in the
absence (rhombus) and presence of IC50 concentration of extract
(open square) with increasing concentration of substrate. The
figure inset represents the percent of inhibition in the presence of
IC50 concentration. Data represent ±S.E.M. for n= 3.
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Figure 5 Effect of calcium concentration on inhibition of
NN-XIb-PLA2 by aqueous stem bark extract of M. indica. The
reaction mixture contained NN-XIb-PLA2 enzyme in 0.05 M
Tri–HCl buffer pH 7.5, and 3–15 mM CaCl2 in final volume. The
reaction was initiated by adding substrate. The reaction was
carried out in the absence (rhombus) and presence of IC50
concentration of extract (open square) with increasing concentra-
tion of calcium. The figure inset represents percentage inhibition in
the presence of the IC50 concentration. Data represent ±S.E.M.
for n= 3.
376 B.L. Dhananjaya et al.induced models of inflammation in mice (Garrido et al., 2004).
It was demonstrated that the extract inhibited the induction of
PGE2 and LTB4, when it was stimulated with pro-
inflammatory stimuli lipopolysaccharide-interferon gamma
(LPS-IFN!) or calcium ionophore A23187 in J774 macro-
phage cell lines (Garrido et al., 2006). Recently, it has been
shown that the aqueous stem bark extract of M. indica admin-
istration had reduced TBARS levels and iNOS, COX-2, TNF-
a and TNF R-2 expression in colonic tissue, and a decrease in
IL-6 and TNF-a serum levels was also observed (Ma´rquez
et al., 2010).
Although the mechanism of action of the extract is unclear,
the finding that no visible change was detected in elec-trophoretic pattern of NN-XIb-PLA2 when incubated with
extracts (data not shown), excludes the proteolytic degradation
as a potential mechanism (Borges et al., 2000). Further, con-
sidering our binding studies, where it has been observed that
the inhibition is irreversible and also independent on substrate
and calcium concentration, the most likely mechanism for
anti-PLA2 activities by this extract could be due to the direct
binding of the constituents of the extract with sPLA2s active
site. The extract is known to contain a well defined and
standardized mixture of components such as polyphenols,
terpenoids, steroids, fatty acids and microelements (Nunez-
Selles et al., 2002; Shah et al., 2010), mangiferin (20%) being
the predominant one. As with other polyphenols, the phenolic
Anti-phospholipase A2 activity of Mangifera indica L. 377constituents of the extract such as phenolic acids (Gallic acid,
3, 4 dihydroxy benzoic acid, benzoic acid) and phenolic esters
(Gallic acid methyl ester, gallic acid propylester, benzoic acid
propyl ester), could be also involved in binding with sPLA2s,
thus bringing about inhibition (Shah et al., 2010). In addition,
the active constituents of this extract such as mangiferin,
amento flavone, friedelin, daucosterol and beta-sitosterol
(Sanchez et al., 2000) seem to exhibit anti-inflammatory and
thus anti-snake effect through quenching of free radicals
(Nanda et al., 2007; Narendra Sharath Chandra et al., 2007;
Garrido et al., 2009; Ma´rquez et al., 2012; Dhananjaya
et al., 2011; Vyas et al., 2012). This anti-inflammatory activity
of the extract was believed to be due to the powerful antioxi-
dant activities exhibited by the constituents such as phenolic
compounds including mangiferin. It has been demonstrated
that VIMANG and mangiferin, exhibit inhibitory activity
against synovial fluid PLA2 activities (Garrido et al., 2004).
The aqueous stem bark extract of M. indica inhibiting both
in vitro PLA2 enzymatic activity and in vivo edema inducing
activity of NN-XIb-PLA2, suggests a strong correlation
between lipolytic activity and pro-inflammatory activity inhibi-
tion. It is to be noted that this standard aqueous stem bark
extract ofM. indica has been tested in a broad set of toxicolog-
ical studies with satisfactory results, including acute and sub-
chronic toxicity, genotoxicity, and irritability and is classified
as a non-toxic product (Sanchez et al., 2000; Gonza´lez et al.,
2007; Garrido et al., 2009). Thus, it can be viewed that M.
indica bark extract can be developed for topical application,
as it is non-toxic and can be developed for effective anti-
snakebite formulation, which contain potent anti-snake venom
molecules. In conclusion, the aqueous extract of M. indica
effectively inhibited svPLA2 and its associated toxic activities.
The inhibition is irreversible and also independent on substrate
and calcium concentration, suggesting that the constituents of
the extract might possibly directly interact to bring about inhi-
bition. Also it was found that there is a strong correlation
between lipolytic activity and pro-inflammatory activity inhibi-
tion. Therefore, the study suggests that the extract possesses
potent anti-PLA2 agents that could be developed as a potential
therapeutic agent against snake envenomation. This study also
substantiates their anti-snake venom properties. Further in-
depth studies on compounds present in the extract that are
responsible for the anti-PLA2 activity will be interesting, as
these are highly attractive candidates for formulation develop-
ment for topical application during snakebite. This supple-
ments the conventional antivenom therapy and helps in
management of snakebite. Further in-depth studies on the role
and mechanism of the principal constituents present in the
extract, responsible for the anti-PLA2 activity can be carried
out to develop them into potent anti-snake component and
also as an anti-inflammatory agent.Acknowledgments
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